Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Metformin + Standard of Care Clear all

Conditions: Menopause, Menopause Hot Flashes, Menopause Related Conditions, Cardiovascular
Interventions: Metformin, semaglutide, Anti-hypertensives, Lipid Lowering Medication, Life style intervention, Fezolinetant, Hormonal therapy; Drug · Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 45 Years to 55 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Aurora, Colorado • Chapel Hill, North Carolina • Richmond, Virginia

Conditions: Type 2 Diabetes Mellitus
Interventions: S-707106 Dose A, S-707106 Dose B, S-707106 Dose C, Placebo A tablet, Metformin; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prediabetes; Complicating Pregnancy
Interventions: Metformin; Drug
Lead sponsor: Gianna Wilkie; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Diabetes Mellitus, Type 2
Interventions: Saxagliptin, Dapagliflozin, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Atrial Fibrillation, Obesity and Obesity-related Medical Conditions
Interventions: Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, Anti-Obesity Medication (AOM) treatment; Procedure · Drug
Lead sponsor: Ali Aminian; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diabetes Mellitus Type 2 in Obese
Interventions: standard of care in general clinical practice; Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 12 Years to 24 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 16
States / cities: Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 11 more

Conditions: Atrial Fibrillation
Interventions: Metformin, Recommendations for lifestyle modification., AliveCor; Drug · Behavioral · Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Diabetes
Interventions: BE-EHR module; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 75 Years and older
Enrollment: 7,630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-small Cell Lung Cancer Stage IIIB/IV, Non-small Cell Lung Cancer Metastatic, Nonsquamous Nonsmall Cell Neoplasm of Lung
Interventions: metformin, carbohydrate restricted diet; Drug · Behavioral
Lead sponsor: Beth Israel Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 4
States / cities: New York, New York

Conditions: Advanced Solid Tumor
Interventions: Metformin; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 10
States / cities: Bay City, Michigan • Clarkston, Michigan • Detroit, Michigan + 7 more

Conditions: Epicardial Fat
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 90 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cervical Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma, HPV (Human Papillomavirus)-Associated Carcinoma
Interventions: HPV vaccine, Imiquimod, and metformin combination therapy; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: Metformin, Lifestyle Modification; Drug · Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2036
U.S. locations: 4
States / cities: Aurora, Colorado • Colorado Springs, Colorado • Denver, Colorado + 1 more

Conditions: Focal Segmental Glomerulosclerosis
Interventions: Metformin + Standard of Care, Placebo + Standard of Care; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: New Haven, Connecticut • New York, New York

Conditions: Low Milk Supply, Pre-diabetes, Insulin Resistance, Suppressed Lactation
Interventions: Standard care, Metformin, Placebo; Behavioral · Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 20 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma
Interventions: Biospecimen Collection, Educational Intervention, Extended Release Metformin Hydrochloride, Questionnaire Administration; Procedure · Other · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 3
States / cities: Duarte, California • La Jolla, California • Riverside, California

Conditions: Sickle Cell Anemia, Sickle Cell Disease, Hemoglobin Disorder
Interventions: Metformin, Questionnaires; Drug · Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 10 Years to 60 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Duke University; Other
Eligibility: 0 Years to 20 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 49
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more

Conditions: Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Carcinoma
Interventions: Biopsy Procedure, Extended Release Metformin Hydrochloride, Megestrol Acetate, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 8
States / cities: Los Angeles, California • Denver, Colorado • Chicago, Illinois + 5 more

Conditions: Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension, Cardiovascular Disease Acute, Hyperlipidemia, Chronic Kidney Disease (CKD), Stages 3-4 Exercise Tolerance / Functional Capacity Vascular Health / Arterial Stiffness Fatigue in CKD, Peripheral Artery Disease, Metabolic Syndrome, Prediabetes
Interventions: Truway Portable Ultrasound Device, Truway Blood Glucose Monitor, Standard Oral Hypoglycemic Agent; Device · Drug
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Cancer
Interventions: Metformin, Placebo, Stereotactic body Radiotherapy (SBRT); Drug · Other · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypertriglyceridemia
Interventions: Omega-3-Acid Ethyl Esters; Drug
Lead sponsor: Jewish Hospital, Cincinnati, Ohio; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Type 2 Diabetes Mellitus
Interventions: Dulaglutide, Placebo, SGLT2 inhibitor, Metformin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 13
States / cities: Encino, California • Huntington Park, California • Los Angeles, California + 9 more

Conditions: Obesity, Adolescent, Pre Diabetes
Interventions: avoid sugary and NNS drinks plus start Metformin, avoid sugary drinks (allowed water and drinks sweetened with NNS) plus start Metformin; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 10 Years to 21 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Gainesville, Florida

Search by objective public record fields.

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy

Metformin Versus Standard of Care Treatment in Pregnant Women With Prediabetes

ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study

Metabolic Surgery for Atrial Fibrillation Elimination

TODAY2 Phase 1 Immediate Post-Intervention Observational Follow-up Study

Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation

A Randomized Trial of a BE-EHR Module to Guide the Care of Older Adults With Diabetes

Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC)

Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies

Semaglutide vs Dulaglutide on Epicardial Adipose Tissue

HPV Vaccine, Imiquimod, and Metformin Combination Trial

Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients

AMPK-activation by Metformin in FSGS: AMP-FSGS

Metformin to Augment Low Milk Supply (MALMS) Study

Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy

Fetal Hemoglobin Induction Treatment Metformin

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer

Truway Diagnostic Tools in Primary Care

Metformin in Non Small Cell Lung Cancer (NSCLC)

Triglyceride Lowering Study

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

Effect of NNS on Metformin/GDF15, Pilot